Norepinephrine reuptake inhibitor
Norepinephrine reuptake inhibitor | |
---|---|
Drug class | |
Synonyms | adrenergic reuptake inhibitor |
External links | |
MeSH | D018759 |
Legal status | |
In Wikidata |
A norepinephrine reuptake inhibitor (NRI, NERI) or noradrenaline reuptake inhibitor or adrenergic reuptake inhibitor (ARI), is a type of
Medical use
NRIs are commonly used in the treatment of conditions like
Depression
A meta analysis published in BMJ in 2011 concluded that the selective NRI reboxetine is indistinguishable from placebo in the treatment of depression.[4] A second review by the European Medicines Agency concluded that reboxetine was significantly more effective than placebo, and that its risk/benefit ratio was positive. The latter review, also examined the efficacy of reboxetine as a function of baseline depression, and concluded that it was effective in severe depression and panic disorder but did not show effects significantly superior to placebo in mild depression.[5]
A closely related type of drug is a norepinephrine releasing agent (NRA).
List of selective NRIs
Many NRIs exist, including the following:
- Selective norepinephrine reuptake inhibitors
- Marketed
- Atomoxetine (Strattera)
- Reboxetine (Edronax, Vestra)
- Viloxazine (Qelbree, Vivalan)
- Never marketed
- Amedalin (UK-3540-1)
- Daledalin (UK-3557-15)
- Edivoxetine (LY-2216684)
- Esreboxetine (AXS-14; PNU-165442G)
- Lortalamine (LM-1404)
- Nisoxetine (LY-94,939)
- Talopram (tasulopram) (Lu 3–010)
- Talsupram (Lu 5–005)
- Tandamine (AY-23,946)
- Marketed
- NRIs with activity at other sites
- Marketed
- Bupropion (Wellbutrin, Zyban)
- Desipramine (Norpramin)
- Maprotiline (Ludiomil)
- Nortriptyline (Pamelor)
- Protriptyline (Vivactil)
- Tapentadol (Nucynta)
- Teniloxazine (Lucelan, Metatone)
- Never marketed
- Ciclazindol (Wy-23,409)
- CP-39,332
- Manifaxine (GW-320,659)
- Radafaxine (GW-353,162)
- Marketed
Note: Only NRIs selective for the NET greater than the other two
See also
References
- PMID 15283948.
- PMID 15526000.
- S2CID 15573624.
- PMID 20940209.
- ^ "MHRA Public Assessment Report" (PDF). Archived from the original (PDF) on 2014-04-27. Retrieved 2014-04-26.
antagonists
receptor agonists
- Beloranib§
- Bimagrumab§
- Desiccated thyroid‡
- Metformin
- Metreleptin
- Naltrexone
- Setmelanotide
- Topiramate
- ZGN-1061
- Zonisamide
- Water
- #WHO-EM
- ‡Withdrawn from market
- Clinical trials:
- †Phase III
- §Never to phase III
| ||
---|---|---|
Non-classical CNS stimulants | ||
α2-adrenoceptor agonists | ||
Antidepressants | ||
Miscellaneous/others | ||
Related articles |
|
| ||
---|---|---|
SNRIs Tooltip Serotonin–norepinephrine reuptake inhibitors | ||
NRIs Tooltip Norepinephrine reuptake inhibitors | ||
NDRIs Tooltip Norepinephrine–dopamine reuptake inhibitors | ||
NaSSAs Tooltip Noradrenergic and specific serotonergic antidepressants | ||
SARIs Tooltip Serotonin antagonist and reuptake inhibitors | ||
SMS Tooltip Serotonin modulator and stimulators | ||
Others |
|
TCAs Tooltip Tricyclic antidepressants |
| |
---|---|---|
TeCAs Tooltip Tetracyclic antidepressants | ||
Others |
|
|
Miscellaneous | |
---|---|
|
- #WHO-EM
- ‡Withdrawn from market
- Clinical trials:
- †Phase III
- §Never to phase III